Immunization, measles second dose in Upper middle income
Upper middle income: Immunization, measles second dose was 84.9% in 2024. ▲ Rising
Immunization, measles second dose in Upper middle income, 2000–2024
Source: WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/). Measured in % of children by the nationally recommended age.
Analysis
In 2024, immunization, measles second dose in Upper middle income stood at 84.9%.
That represents a change of up 2.1% on the previous year and up 3.4% over ten years.
Over the whole period, immunization, measles second dose in Upper middle income peaked at 88.0% in 2018 and was at its lowest, 25.4%, in 2000.
Upper middle income ranks 16th of 43 groups on this measure, in the middle of the range.
The long-run direction has been consistently rising across the 25 years of available data.
Immunization, measles second dose in Upper middle income, year by year
| Year | % of children by the nationally recommended age | Change |
|---|---|---|
| 2000 | 25.4% | — |
| 2001 | 29.9% | +17.5% |
| 2002 | 28.9% | -3.2% |
| 2003 | 31.5% | +9.0% |
| 2004 | 32.6% | +3.7% |
| 2005 | 65.3% | +100.2% |
| 2006 | 71.6% | +9.5% |
| 2007 | 73.9% | +3.3% |
| 2008 | 78.0% | +5.5% |
| 2009 | 81.6% | +4.6% |
| 2010 | 81.9% | +0.3% |
| 2011 | 85.2% | +4.1% |
| 2012 | 84.7% | -0.6% |
| 2013 | 84.0% | -0.8% |
| 2014 | 82.1% | -2.3% |
| 2015 | 82.6% | +0.6% |
| 2016 | 86.0% | +4.1% |
| 2017 | 85.8% | -0.3% |
| 2018 | 88.0% | +2.5% |
| 2019 | 84.9% | -3.5% |
| 2020 | 83.5% | -1.6% |
| 2021 | 82.5% | -1.2% |
| 2022 | 84.8% | +2.8% |
| 2023 | 83.1% | -2.0% |
| 2024 | 84.9% | +2.1% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 51.9% | 25.4% | 81.6% | 10 |
| 2010s | 84.5% | 81.9% | 88.0% | 10 |
| 2020s | 83.8% | 82.5% | 84.9% | 5 |
Countries ranked near Upper middle income
More health data for Upper middle income
- Population ages 35-39, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 40-44, male, annual growth rate 1.94 % change on previous year (2025)
- Population ages 40-44, female, per capita 0.0359 units per person (2025)
- Population ages 40-44, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 40-44, female, annual growth rate 1.71 % change on previous year (2025)
- Population ages 35-39, male, per capita 0.0413 units per person (2025)
- Population ages 35-39, male, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 35-39, male, annual growth rate 2.11 % change on previous year (2025)
- Population ages 35-39, female, per capita 0.0394 units per person (2025)
- Population ages 30-34, female, annual growth rate -3.39 % change on previous year (2025)
Frequently asked questions
- What is immunization, measles second dose in Upper middle income?
- Immunization, measles second dose in Upper middle income was 84.9% in 2024, according to WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/).
- What is the highest immunization, measles second dose recorded in Upper middle income?
- The highest recorded value was 88.0% in 2018.
- What is the lowest immunization, measles second dose recorded in Upper middle income?
- The lowest recorded value was 25.4% in 2000.
- How does Upper middle income rank for immunization, measles second dose?
- Upper middle income ranks 16th out of 43 groups with data for 2024.
- Is immunization, measles second dose rising or falling in Upper middle income?
- Over the last ten years it is up 3.4%. The long-run trend across the full record is rising.
- Where does this Upper middle income data come from?
- The figures come from WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/), published as part of Immunization, measles second dose (% of children by the nationally recommended age). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).
About this data
Child immunization, measles second dose, measures the percentage of children who received two dose of measles containing vaccine according to nationally recommended schedule through routine immunization services in a given year.